Clinical trials: Interstitial Fibrosis

Idiopathic Pulmonary Fibrosis

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis

• Completed
• Age: 40 years and older
• Phase 2
• Results posted

Primary Objective: To evaluate, in comparison with placebo, the efficacy of 2 dose levels/regimens of SAR156597 administered subcutaneously during 52 weeks on lung function of participants with Idiopathic Pulmonary Fibrosis…

Trial name

ESTAIR (NCT02345070)

Testing

SAR156597

Where

101 sites in United States, Argentina and 17 more

Volunteers

327 people

Sponsor

Sanofi